StockNews.AI
PFE
StockNews.AI
140 days

European Commission Approves Pfizer's RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease

1. Pfizer's ABRYSVO vaccine now approved for adults aged 18-59. 2. This decision expands market access beyond older adults.

2m saved
Insight
Article

FAQ

Why Bullish?

The expansion of ABRYSVO's indication potentially increases revenue for PFE, similar to past vaccine approvals boosting sales.

How important is it?

The approval significant expands PFE's market share for RSV vaccines, indicating strong future sales potential.

Why Long Term?

Extended usage likely leads to sustained revenue growth for several years, paralleling successful vaccine market patterns.

Related Companies

MRNAJNJGSK
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO®, the company's bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, to extend the indication to include prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age. This expands the previous authorization for individuals aged 60 and older, and ABRYSVO now.

Related News